<p>Panel A) HIV-Env subtype A (UG37) and panel B) HIV-Env subtype B (6101) specific IgG antibody titers were assessed at baseline, post prime and post boost. Black and Red arrows indicate vaccination times for Groups 1–3 and Groups 4–5, respectively.</p
<p>W = week, W0 and W24 are vaccination visits.</p>a<p>(V/P) Number of Vaccine recipients/number o...
<p>Reciprocal titers of IgG binding antibody responses to (A) gp120 A244gD (CRF01_AE), (B) gp70V1V2 ...
<div><p></p><p>In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variab...
<p>The geometric mean of a) anti-ENV Subtype A (UG037)- and b) anti-p24 (IIIB)-specific antibody tit...
<p>Antibody responses were measured using ELISA against HIV-1 envelope proteins matching vaccine ant...
<p>(a) Mean anti-Env endpoint titers (4 animals/group) against JR-FL foldon trimer were determined o...
<p>Percent of positive IgG responders to gp120 A244gD (CRF01_AE), gp70V1V2 92TH023 (CRF01_AE) and gp...
Neutralization sensitivities of contemporary U.S. subtype B pseudoviruses (PSVs) (2017–18) were comp...
<p>ID<sub>50</sub> values were determined by TZM-bl assay from serum samples of Group A (red in colo...
<p>Reciprocal titers of IgG binding antibody responses to (A) gp120 A244gD (CRF01_AE), (B) gp70V1V2 ...
Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a protective HIV v...
In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 an...
Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a protective HIV v...
<div><p>Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a protecti...
<p>Binding of mouse antisera from DNA prime-protein boosts with subtypes A, B C and D envelope DNA a...
<p>W = week, W0 and W24 are vaccination visits.</p>a<p>(V/P) Number of Vaccine recipients/number o...
<p>Reciprocal titers of IgG binding antibody responses to (A) gp120 A244gD (CRF01_AE), (B) gp70V1V2 ...
<div><p></p><p>In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variab...
<p>The geometric mean of a) anti-ENV Subtype A (UG037)- and b) anti-p24 (IIIB)-specific antibody tit...
<p>Antibody responses were measured using ELISA against HIV-1 envelope proteins matching vaccine ant...
<p>(a) Mean anti-Env endpoint titers (4 animals/group) against JR-FL foldon trimer were determined o...
<p>Percent of positive IgG responders to gp120 A244gD (CRF01_AE), gp70V1V2 92TH023 (CRF01_AE) and gp...
Neutralization sensitivities of contemporary U.S. subtype B pseudoviruses (PSVs) (2017–18) were comp...
<p>ID<sub>50</sub> values were determined by TZM-bl assay from serum samples of Group A (red in colo...
<p>Reciprocal titers of IgG binding antibody responses to (A) gp120 A244gD (CRF01_AE), (B) gp70V1V2 ...
Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a protective HIV v...
In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 an...
Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a protective HIV v...
<div><p>Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a protecti...
<p>Binding of mouse antisera from DNA prime-protein boosts with subtypes A, B C and D envelope DNA a...
<p>W = week, W0 and W24 are vaccination visits.</p>a<p>(V/P) Number of Vaccine recipients/number o...
<p>Reciprocal titers of IgG binding antibody responses to (A) gp120 A244gD (CRF01_AE), (B) gp70V1V2 ...
<div><p></p><p>In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variab...